Plants as factories for human pharmaceuticals: Applications and challenges

Jian Yao, Yunqi Weng, Alexia Dickey, Kevin Yueju Wang

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A number of therapeutic proteins have been produced in plants, some of which have been through pre-clinical or clinical trials and are close to commercialization. Plants have the potential to mass-produce pharmaceutical products with less cost than traditional methods. Tobacco-derived antibodies have been tested and used to combat the Ebola outbreak in Africa. Genetically engineered immunoadhesin (DPP4-Fc) produced in green plants has been shown to be able to bind to MERS-CoV (Middle East Respiratory Syndrome), preventing the virus from infecting lung cells. Biosafety concerns (such as pollen contamination and immunogenicity of plant-specific glycans) and costly downstream extraction and purification requirements, however, have hampered PMF production from moving from the laboratory to industrial application. In this review, the challenges and opportunities of PMF are discussed. Topics addressed include; transformation and expression systems, plant bioreactors, safety concerns, and various opportunities to produce topical applications and health supplements.

Original languageEnglish
Pages (from-to)28549-28565
Number of pages17
JournalInternational Journal of Molecular Sciences
Volume16
Issue number12
DOIs
StatePublished - 2 Dec 2015
Externally publishedYes

Fingerprint

industrial plants
Drug products
Industrial plants
Molecular Farming
Middle East
proteins
Proteins
pollen
bioreactors
tobacco
combat
commercialization
Tobacco
supplements
viruses
Bioreactors
antibodies
Viruses
purification
Antibodies

Keywords

  • Edible vaccine
  • Humanized glycan
  • Plant molecular farming
  • Seed platform
  • Transient expression

Cite this

Yao, Jian ; Weng, Yunqi ; Dickey, Alexia ; Wang, Kevin Yueju. / Plants as factories for human pharmaceuticals : Applications and challenges. In: International Journal of Molecular Sciences. 2015 ; Vol. 16, No. 12. pp. 28549-28565.
@article{cb6a0b0a8cd44da3852926b8ba9ab190,
title = "Plants as factories for human pharmaceuticals: Applications and challenges",
abstract = "Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A number of therapeutic proteins have been produced in plants, some of which have been through pre-clinical or clinical trials and are close to commercialization. Plants have the potential to mass-produce pharmaceutical products with less cost than traditional methods. Tobacco-derived antibodies have been tested and used to combat the Ebola outbreak in Africa. Genetically engineered immunoadhesin (DPP4-Fc) produced in green plants has been shown to be able to bind to MERS-CoV (Middle East Respiratory Syndrome), preventing the virus from infecting lung cells. Biosafety concerns (such as pollen contamination and immunogenicity of plant-specific glycans) and costly downstream extraction and purification requirements, however, have hampered PMF production from moving from the laboratory to industrial application. In this review, the challenges and opportunities of PMF are discussed. Topics addressed include; transformation and expression systems, plant bioreactors, safety concerns, and various opportunities to produce topical applications and health supplements.",
keywords = "Edible vaccine, Humanized glycan, Plant molecular farming, Seed platform, Transient expression",
author = "Jian Yao and Yunqi Weng and Alexia Dickey and Wang, {Kevin Yueju}",
year = "2015",
month = "12",
day = "2",
doi = "10.3390/ijms161226122",
language = "English",
volume = "16",
pages = "28549--28565",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

Plants as factories for human pharmaceuticals : Applications and challenges. / Yao, Jian; Weng, Yunqi; Dickey, Alexia; Wang, Kevin Yueju.

In: International Journal of Molecular Sciences, Vol. 16, No. 12, 02.12.2015, p. 28549-28565.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Plants as factories for human pharmaceuticals

T2 - Applications and challenges

AU - Yao, Jian

AU - Weng, Yunqi

AU - Dickey, Alexia

AU - Wang, Kevin Yueju

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A number of therapeutic proteins have been produced in plants, some of which have been through pre-clinical or clinical trials and are close to commercialization. Plants have the potential to mass-produce pharmaceutical products with less cost than traditional methods. Tobacco-derived antibodies have been tested and used to combat the Ebola outbreak in Africa. Genetically engineered immunoadhesin (DPP4-Fc) produced in green plants has been shown to be able to bind to MERS-CoV (Middle East Respiratory Syndrome), preventing the virus from infecting lung cells. Biosafety concerns (such as pollen contamination and immunogenicity of plant-specific glycans) and costly downstream extraction and purification requirements, however, have hampered PMF production from moving from the laboratory to industrial application. In this review, the challenges and opportunities of PMF are discussed. Topics addressed include; transformation and expression systems, plant bioreactors, safety concerns, and various opportunities to produce topical applications and health supplements.

AB - Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A number of therapeutic proteins have been produced in plants, some of which have been through pre-clinical or clinical trials and are close to commercialization. Plants have the potential to mass-produce pharmaceutical products with less cost than traditional methods. Tobacco-derived antibodies have been tested and used to combat the Ebola outbreak in Africa. Genetically engineered immunoadhesin (DPP4-Fc) produced in green plants has been shown to be able to bind to MERS-CoV (Middle East Respiratory Syndrome), preventing the virus from infecting lung cells. Biosafety concerns (such as pollen contamination and immunogenicity of plant-specific glycans) and costly downstream extraction and purification requirements, however, have hampered PMF production from moving from the laboratory to industrial application. In this review, the challenges and opportunities of PMF are discussed. Topics addressed include; transformation and expression systems, plant bioreactors, safety concerns, and various opportunities to produce topical applications and health supplements.

KW - Edible vaccine

KW - Humanized glycan

KW - Plant molecular farming

KW - Seed platform

KW - Transient expression

UR - http://www.scopus.com/inward/record.url?scp=84949472031&partnerID=8YFLogxK

U2 - 10.3390/ijms161226122

DO - 10.3390/ijms161226122

M3 - Review article

C2 - 26633378

AN - SCOPUS:84949472031

VL - 16

SP - 28549

EP - 28565

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

ER -